EVOTF — Evotec SE
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1412558 ·
Germany
Last close
$3.33
Market Cap
$590.83M
52W High
$8.01
52W Low
$3.33
ADV30
0
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 164,926,000 | 19,795,000 | -27,115,000 | -26,744,000 | 1,504,970,000 | 299,012,000 | 863,309,000 |
| Jun 2026 | 143,479,000 | -1,579,000 | -89,322,000 | -46,649,000 | 1,573,975,000 | 348,356,000 | 908,397,000 |
| Mar 2026 | 156,644,000 | -1,569,000 | -46,423,000 | -121,936,000 | 1,639,812,000 | 387,912,000 | 940,192,000 |
| Dec 2025 | 253,273,000 | 78,463,000 | 37,208,000 | 14,624,000 | 1,713,945,000 | 401,786,000 | 900,241,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,390,000
Investing CF
$237,187,000
Financing CF
$-23,201,000
CapEx
$-45,331,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-1.11
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-971,215,000
Inventory
$37,710,000
Receivables
$171,272,000
ST Investments
$119,466,000
EBIT TTM
$-149,641,000
Pretax Income TTM
$-162,860,000
Interest Exp TTM
$13,219,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$717,283,008
EBITDA
$-73,181,000
Free Cash Flow
$-80,990,624
Enterprise Value
$701,518,784
Total Cash
$465,587,008
Total Debt
$475,865,984
Shares Out
177,694,559
Trailing EPS
$-1.26
Book Value
$4.35
ROE
-26.1%
ROA
-5.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 788,373,000 | -55,818,000 | -103,517,000 | 1,713,945,000 | 900,241,000 | 813,704,000 | -9,179,000 |
| Dec 2024 | 796,967,000 | -78,919,000 | -196,078,000 | 1,912,502,000 | 959,977,000 | 952,525,000 | 18,220,000 |
| Dec 2023 | 781,426,000 | -26,628,000 | -83,913,000 | 2,252,468,000 | 1,132,560,000 | 1,119,908,000 | 36,439,000 |
| Dec 2022 | 751,448,000 | 20,850,000 | -175,655,000 | 2,257,247,000 | 1,070,063,000 | 1,187,184,000 | 205,811,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMX | Immix Biopharma, Inc. | $603.45M | $7.20 | — |
| CLYM | Climb Bio, Inc. | $574.46M | $9.78 | — |
| ABUS | Arbutus Biopharma Corp | $620.84M | $4.05 | — |
| WVE | Wave Life Sciences, Inc. | $560.13M | $2.84 | — |
| ZVRA | ZEVRA THERAPEUTICS, INC. | $559.34M | $9.40 | — |
News headlines (Yahoo Finance, 1h cache)
Evotec SE (EVOTF) (Q3 2026) Earnings Call Highlights: Near-Breakeven EBITDA, Horizon Savings ...
2026-11-06 01:16 · Yahoo
Here's Why Evotec (EVO) Looks Ripe for Bottom Fishing
2026-11-18 13:55 · Yahoo
Non-Animal Alternative Testing - Global Strategic Business Report 2026: Capitalize on 13.3% CAGR and $4.7B by 2032 as Abbott, Charles River, Emulate, Evotec, and Bio-Rad Reshape Testing
2026-11-16 15:45 · Yahoo
Evotec Secures $2.9 Million Grant to Advance Early Drug Safety Testing Using Human Stem Cell Technology
2026-11-16 06:57 · Yahoo
Evotec SE (EVO) Q3 2026 Earnings Call Transcript
2026-11-05 21:14 · Yahoo
What Evotec (EVO) Said on Its Q3 Earnings Call
2026-11-05 20:14 · Yahoo
Evotec Reports Third Quarter and Nine-Month 2026 Results: Building Growth Momentum Toward 2030 Goals
2026-11-05 07:18 · Yahoo
Evotec SE to Announce Results for the First Nine Months 2026 on November 5, 2026
2026-10-29 07:00 · Yahoo
Did Evotec’s 60% Drop Catch You Out? What Investors Missed
2026-10-25 16:06 · Yahoo
Evotec Appoints Dr. Joanna Holbrook as Chief Scientific Officer and Member of the Management Board
2026-10-15 06:04 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.